概括
将普拉诺洛尔添加到性心症中,可以降低缺血期间的代谢活动,并改善缺血后的心脏功能. 单次高剂量普罗普拉诺洛尔足以获得这些好处.
科学领域:
- 心脏病学 心脏病学
- 心血管外科心血管外科
- 药理学 药理学是指药理学的学科.
背景情况:
- 在心脏手术期间,性心脏损伤对于心肌保护至关重要.
- 需要进一步阐明β-阻断剂 (如普拉诺洛尔) 与心脏相关的作用.
- 优化心肌保护策略对于改善手术结果至关重要.
研究的目的:
- 为了研究醇与多剂量性心脏的结合对心肌保护的影响.
- 评估不同剂量和服用时间对心脏功能和缺血损伤的影响.
- 为了确定propranolol是否增强性心脏的保护作用.
主要方法:
- 32个在位狗心经历了90分钟的冷全球缺血,随后进行60分钟的再注射.
- 心脏被分为四组:对照组,低剂量普罗普兰诺洛,高剂量普罗普兰诺洛和高剂量普罗普兰诺洛与初始输液.
- 对心肌二氧化碳 (PmCO2) 进行监测,并测量心脏功能 (发达压力,dP/dt,EDP).
- 电子显微镜评估了缺血性损伤.
主要成果:
- 与对照组相比,用普罗普拉诺洛尔 (组2,3,4) 在缺血期间显著降低了心肌CO2峰值 (组1).
- 与对照组相比,高剂量普拉诺洛尔 (组3,4) 在再输血后显著改善了末端透气压.
- 接受高剂量普拉诺洛尔的心脏在电子显微镜上显示出较少的缺血损伤.
- 缩功能 (发达的压力,dP/dt) 没有被propranolol抑制.
结论:
- 当添加到多剂量性心肌时,罗可有效地降低缺血期间的代谢活动.
- 高剂量的普拉诺洛尔可以在再输液过程中改善心室合规性,而不会影响缩功能.
- 一次高剂量的普拉诺洛尔似乎足够,后续剂量没有额外的益处.
相关概念视频
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...


